DNA-PK, ATM and MDR proteins inhibitors in overcoming fludarabine resistance in CLL cells

Experimental Oncology

Volumn 32, Issue 4, 2010, Pages 258-262

  Svirnovski, A I ^a   Serhiyenka, T F ^a   Kustanovich, A M ^b   Khlebko, P V ^a   Fedosenko, V V ^b   Taras, I B ^a   Bakun, A V ^a  

^a Republic Center for Hematology and Transfusiology   (Belarus)

^b Belarusian Research Center for Pediatric Oncology and Hematology   (Belarus)

Author keywords

Caffeine; Fludarabine; Leukemia; NU7026; Resistance; Vanillin

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYL 2H TETRAZOLIUM BROMIDE; ATM PROTEIN; ATR PROTEIN; BROMINE DERIVATIVE; CAFFEINE; CYCLOSPORIN A; DNA DEPENDENT PROTEIN KINASE; FLUDARABEL; FLUDARABINE; GLYCOPROTEIN P; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; NU 7026; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN; PROTEIN BCL XS; UNCLASSIFIED DRUG; VANILLIN;

ARTICLE; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE; PROTEIN EXPRESSION; PROTEIN FUNCTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BENZALDEHYDES; BLOTTING, WESTERN; CAFFEINE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CHROMONES; CYCLOSPORINE; DNA-ACTIVATED PROTEIN KINASE; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MORPHOLINES; P-GLYCOPROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS; VIDARABINE;

EID: 78650702851     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112: 975-80.
2. Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophophamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007; 25: 793-8.
3. Catovsky d., Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukemia (the LRF CLL4 Trial): a randomized controlled trial. Lancet 2007; 370: 230-9.
4. Wierda W, O'Brien S, Faderl S, et al. A retrospective comparison of three sequential groups of patients with recurrent /refractory chronic lymphocytic leukemia treated with fludarabine- based regimens. Cancer 2006; 106: 337-45.
5. Osterborg A, Kipps TJ, Mayer J, et al. Ofatumumab (HuMax-CD20), a novel CD20 monoclonal antibody, is an active treatment for patients with CLL refractory to both fludarabine and alemtuzumab or bulky fludarabine-refractory disease: results from the planned interim analysis of an international pivotal trial. Blood 2008; 112: Abstract#328.
6. Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous alemtuzumab (Campath) in fludarabine-refractory CLL: final results of CLL2H trial of the GCLLSG and comprehensive analysis of prognostic markers. Blood 2008; 112: Abstract #329.
7. Sampath D, Plunkett W. The role of DNA repair in chronic lymphocytic leukemia pathogenesis and chemotherapy resistance. Current Oncology Reports 2007; 9: 361-7.
8. O'Brien S. New agents in the treatment of CLL. Hematology Am Soc Hematol Educ Program. 2008; 1: 457-64.
9. Lopez-Guerra M, Trigueros-Motos L, Moloina - Arcas M, et al. Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells. Haematologica 2008; 93: 1843-51.
10. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood 2008; 111: 5446-56.
11. Willmore E, Summerfield GP, Mainou-Fowler T, et al. Sensitization of B-CLL cells to chlorambucil and fludarabine via inhibition of the DNA damage sensor proteins, DNA-PK and ATM. Proc Amer Assoc Cancer Res 2006; 47: Abstract #518.
12. Willmore E, Elliott SL, Mainou-Fowler T, et al. DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia. Clinical Cancer Research 2008; 14: 3984.
13. de Campos-Nebel M, Larripa I, G onzález-Cid M. Non-homologous end joining is the responsible pathway for the repair of fludarabine-induced DNA double strand breaks in mammalian cells. Mutation Research 2008; 646: 8-16.
14. Molina-Arcas M, Bellosillo B, Casado FJ, et al. Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia. Blood 2003; 101: 2328-34.
15. Tsang RY, Santos C, Ghosh S, et al. Immunohistochemistry for human concentrative nucleoside transporter 3 protein predicts fludarabine sensitivity in chronic lymphocytic leukemia. Modern Pathol 2008; 21: 1387-93.
16. Klöpfer A, Hasenjäger A, Belka C, et al. Adenine deoxynucleotides fludarabine and cladribine induce apoptosis in a CD95/Fas receptor, FADD and caspase-8-independent manner by activation of the mitochondrial cell death pathway. Oncogene 2004; 23: 9408-18.
17. Silva KL, Vasconcellos DV, de Paula Castro ED, et al. Apoptotic effect of fludarabine is independent of expression of IAPs in B-cell chronic lymphocytic leukemia. Apoptosis 2006; 11: 277-85.
18. Faria JR, Yamamoto M, Faria RMD, et al. Fludarabine induces apoptosis in chronic lymphocytic leukemia - the role of P53, Bcl-2, Bax, Mcl-1, and Bag-1 proteins Braz J Med Biol Res 2006; 39: 327-33.
19. Svirnovski AI, Shman TV, Serghiyenka TF, et al. ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells. Hematology 2009; 14: 204-12.
20. Svirnovski AI, Serghiyenka TF, Smirnova LA, et al. Prediction of chronic lymphocytic leukemia patient's response to therapy by leukemia cells drug resistance ex vivo. Zdravookhranenie 2010; 3: 57-60 (in Russian).